Literature DB >> 6202770

Immunohistochemical distribution of the antigenic determinants detected by monoclonal antibodies to carcinoembryonic antigen.

A Yachi, K Imai, H Fujita, Y Moriya, M Tanda, T Endo, M Tsujisaki, M Kawaharada.   

Abstract

By using four distinct monoclonal antibodies to CEA, the molecular profile of which was clarified in our accompanying companion paper, immunohistochemical distribution of the antigenic determinants on both cancerous and noncancerous tissues as well as fetal tissues was studied with the use of the immunoperoxidase method. All of the monoclonal antibodies recognize different antigenic determinants on the tissue section. None of the antibodies stained granulocytes in the peripheral blood or in the normal liver tissues tested. Three of our monoclonal antibodies stained columnar epithelial cells in morphologically normal colonic mucosa; however, monoclonal antibody YK024 did not stain them. This antibody was also found to be unreactive with intestinal metaplasia lesions of the stomach, but reacted with a 16-wk-old fetal stomach as well as with cancerous parts of the colon and of the stomach. Moreover, it was found that this monoclonal antibody mainly reacted with moderately or poorly differentiated adenocarcinoma lesions of the colon and the stomach. Periodic acid treatment in this study, together with trypsin treatment on the antigen as described in our accompanying companion paper, may suggest that this antibody recognizes the carbohydrate antigenic determinant in nature.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6202770

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  8 in total

1.  Commercial polyclonal and monoclonal histostaining PAP kits. Immunoperoxidase reagents and performance characteristics in comparison with self-prepared immunoreagents.

Authors:  W D Kuhlmann; P Peschke
Journal:  Histochemistry       Date:  1985

2.  A stomach oncofetal antigen recognized by monoclonal antibody GC302.

Authors:  T Watanabe; M Nishikimi; S Akiyama; J Sakamoto; H Shiku; H Ichihashi; T Ozawa; T Kondo; H Takagi
Journal:  Jpn J Surg       Date:  1987-11

3.  Monoclonal antibodies against CEA-related components discriminate between pancreatic duct type carcinomas and nonneoplastic duct lesions as well as nonduct type neoplasias.

Authors:  B Bätge; K Bosslet; H H Sedlacek; H F Kern; G Klöppel
Journal:  Virchows Arch A Pathol Anat Histopathol       Date:  1986

4.  Preparation and characterization of anti-anti-idiotypic monoclonal antibody ("Ab1-like Ab3") in relation to carcinoembryonic antigen.

Authors:  Masayuki Tsujisaki; Jiro Masuya; Yoshimasa Okada; Tsuneharu Jinnohara; Shigeru Sasaki; Akira Yachi; Kohzoh Imai
Journal:  J Clin Lab Anal       Date:  2002       Impact factor: 2.352

5.  Human pancreatic adenocarcinoma-associated antigens defined by novel murine monoclonal antibodies Pak-1 and Pak-2.

Authors:  K Makisumi; K Takahashi; S Takako; S Sonoda
Journal:  Gastroenterol Jpn       Date:  1990-04

6.  A tumor-associated antigen in the scirrhous gastric carcinoma cell line MK-01 defined by monoclonal antibody S202.

Authors:  T Yokota; T Masuko; T Yamaguchi; K Kitamura; T Takahashi; Y Hashimoto
Journal:  Jpn J Surg       Date:  1989-07

7.  A monoclonal antibody with binding and inhibiting activity towards human pancreatic carcinoma cells. I. Immunohistological and immunochemical characterization of a murine monoclonal antibody selecting for well differentiated adenocarcinomas of the pancreas.

Authors:  K Bosslet; H F Kern; E J Kanzy; A Steinstraesser; A Schwarz; G Lüben; H U Schorlemmer; H H Sedlacek
Journal:  Cancer Immunol Immunother       Date:  1986       Impact factor: 6.968

8.  Epitopes predominantly retained on the carcinoembryonic antigen molecules in plasma of patients with malignant tumors but not on those in plasma of normal individuals.

Authors:  M Kuroki; M Murakami; M Wakisaka; A Krop-Watorek; S Oikawa; H Nakazato; G Kosaki; Y Matsuoka
Journal:  Jpn J Cancer Res       Date:  1992-05
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.